齐达巴坦研究进展

Research Progress of Zidebactam

齐达巴坦(zidebactam),别名WCK5107,是印度沃克哈特(Wockhardt)公司开发的新型β-内酰胺酶抑制剂,具有双重作用机制。2022年,沃克哈特公司向中国提交了WCK-5222临床申报,治疗用于治疗成人复杂性尿路感染(包括急性肾盂肾炎),同年获得批准临床。作者从现有文献中,提取齐达巴坦最新临床前和临床研究进展,从药物作用机制、临床前药理学、药代动力学等方面作一综述,为医药工作者提供参考。

Zidebactam,formerly described as WCK5107,was reseached and developed by an Lndian company Wockhardt.Zidebactam is a novel non-β-lactam bicyclo-acyl hydrazide that has a dual mechanism of action.In 2022,a clinical application for wck-5222 was submitted in China by Wockhardt,and the approval was granted for complicated urinary tract infections in adults,including acute pyelonephritis.This review focuses on its drug action mechanism,preclinical pharmacology,and pharmacokinetics,which was extracting the latest preclinical and clinical research progress of zidabatam from existing literature,and expect to provide information for pharmaceutical workers.